CCG-1423 NEW
| Price | $32 | $52 | $97 |
| Package | 5mg | 10mg | 25mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: CCG-1423 | CAS No.: 285986-88-1 |
| Purity: 99.98% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | CCG-1423 |
| Description | CCG-1423, a selective RhoA pathway inhibitor, suppresses SRF-mediated transcription. |
| Cell Research | Cells in normal culture medium are plated (2,000 per well) in a 96-well plate coated with laminin. After attachment, the medium is replaced with serum-free medium (0% FBS) with 30 μmol/L LPA with or without 300 nM CCG-1423. Fresh LPA with or without CCG-1423 is added at day 5 to ensure that LPA and compound are present throughout the experiment. On day 8, WST-1 reagent is added to the wells for 1 h and absorbance at 450 nm is read using a Victor plate reader.(Only for Reference) |
| In vivo | In H9c2 cells, CCG-1423 inhibits MRTF nuclear localization and completely blocks the activity of STARS proximal reporter genes. It also suppresses TGF-β-induced fibrogenesis in human colon myofibroblasts. Under the influence of CCG-1423 and LY294002, mouse embryonic stem cells differentiate into the mesendoderm. In melanoma cells (A375M2 and SK-Mel-147) overexpressing RhoC, CCG-1423 selectively inhibits cell proliferation. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | Ethanol : 4 mg/mL (8.79 mM), Heating is recommended. H2O : < 1 mg/mL (insoluble or slightly soluble) DMSO : 83 mg/mL (182.5 mM) |
| Keywords | PC-3 | conformational restriction | mice | Inhibitor | bioisostere | CCG-1423 | CCG 1423 | glucose tolerance | metastasis | Apoptosis | inhibit | prostate,serum | Ras |
| Inhibitors Related | Adagrasib | BI-2493 | CCG-257081 | Ketoconazole | SKLB-163 | MRTX1133 | Salirasib | GNE-7915 | RMC-6236 | (S)-(-)-Perillyl alcohol | CASIN | Sotorasib |
| Related Compound Libraries | Anti-Neurodegenerative Disease Compound Library | Bioactive Compound Library | Pain-Related Compound Library | Membrane Protein-targeted Compound Library | Kinase Inhibitor Library | Inhibitor Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $36.00/2mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2024-11-19 | |
| $1520.00/25mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2024-10-23 | |
| $1.00/1KG |
VIP7Y
|
Career Henan Chemical Co
|
2019-09-05 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY